Patents by Inventor Yingda Ye

Yingda Ye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic heteroaryl compounds as sting activators
    Patent number: 11912722
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: February 27, 2024
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • Bicyclic amines as CDK2 inhibitors
    Patent number: 11851426
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: December 26, 2023
    Assignee: Incyte Corporation
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Liangxing Wu, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 11713317
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: March 2, 2021
    Date of Patent: August 1, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20220194931
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: February 15, 2022
    Publication date: June 23, 2022
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
    Publication number: 20220073509
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: March 2, 2021
    Publication date: March 10, 2022
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • TRICYCLIC HETEROARYL COMPOUNDS AS STING ACTIVATORS
    Publication number: 20210332067
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: May 4, 2021
    Publication date: October 28, 2021
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 11136326
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: October 5, 2021
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • Tricyclic heteroaryl compounds as STING activators
    Patent number: 11008344
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: May 18, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • BICYCLIC AMINES AS CDK2 INHIBITORS
    Publication number: 20210107901
    Abstract: The present application provides bicyclic amines that are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 15, 2021
    Inventors: Yingda Ye, Zhenwu Li, Ding-Quan Qian, Sarah Winterton, Kaijiong Xiao, Liangxing Wu, Wenqing Yao, Joshua Hummel, Meizhong Xu, Min Ye, Yingnan Chen, Margaret Favata, Yvonne Lo
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210107900
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: August 18, 2020
    Publication date: April 15, 2021
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao
  • Tricyclic heterocyclic compounds as sting activators
    Patent number: 10947227
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE
    Publication number: 20200397893
    Abstract: Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.
    Type: Application
    Filed: September 1, 2020
    Publication date: December 24, 2020
    Inventors: Phillip C. Liu, Alla Volgina, Richard Wynn, Nina Zolotarjova, Liangxing Wu, Kaijiong Xiao, Song Mei, Liang Lu, Wenyu Zhu, Yingda Ye, Haisheng Wang, Ding-Quan Qian, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20200306256
    Abstract: The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: October 1, 2020
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • Heterocyclic compounds and uses thereof
    Patent number: 10723705
    Abstract: The present disclosure relates to heterocyclic compounds, and pharmaceutical compositions of the same, that are modulators/inhibitors of HDACs, such as HDAC8 and are useful in the treatment of HDAC-associated diseases.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: July 28, 2020
    Assignee: Incyte Corporation
    Inventors: Jun Pan, Xiaozhao Wang, Joseph Barbosa, Wenqing Yao, Yingda Ye
  • PYRROLOPYRIMIDINE DERIVATIVES AS TAM INHIBITORS
    Publication number: 20200181151
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Application
    Filed: November 15, 2019
    Publication date: June 11, 2020
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Taisheng Huang, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • TRICYCLIC HETERARYL COMPOUNDS AS STING ACTIVATORS
    Publication number: 20200040009
    Abstract: The present application provides tricyclic heteroaryl compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Inventors: Liangxing Wu, Yingda Ye, Wenqing Yao
  • Pyrrolopyrimidine derivatives as TAM inhibitors
    Patent number: 10519163
    Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, David M. Burns, Hao Feng, Joseph Glenn, Chunhong He, Song Mei, Jun Pan, Xiaozhao Wang, Yingda Ye
  • TRICYCLIC HETEROCYCLIC COMPOUNDS AS STING ACTIVATORS
    Publication number: 20190359608
    Abstract: The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
    Type: Application
    Filed: May 24, 2019
    Publication date: November 28, 2019
    Inventors: Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
  • BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS
    Publication number: 20190269693
    Abstract: The present disclosure relates to bicyclic heterocycles of Formula (I?), and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 and/or FGFR4 enzyme and are useful in the treatment of FGFR-associated diseases.
    Type: Application
    Filed: February 15, 2019
    Publication date: September 5, 2019
    Inventors: Liang Lu, Bo Shen, Alexander Sokolsky, Xiaozhao Wang, Liangxing Wu, Wenqing Yao, Yingda Ye
  • HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20190225601
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: April 2, 2019
    Publication date: July 25, 2019
    Inventors: Liangxing Wu, Jingwei Li, Chao Qi, Fenglei Zhang, Zhenwu Li, Wenyu Zhu, Zhiyong Yu, Kaijiong Xiao, Liang Lu, Song Mei, Ding-Quan Qian, Chunhong He, Yingda Ye, Meizhong Xu, Wenqing Yao